Connection

GUILLERMINA LOZANO to Mice, Inbred C57BL

This is a "connection" page, showing publications GUILLERMINA LOZANO has written about Mice, Inbred C57BL.
Connection Strength

1.034
  1. Oncogenic KRAS Recruits an Expansive Transcriptional Network through Mutant p53 to Drive Pancreatic Cancer Metastasis. Cancer Discov. 2021 08; 11(8):2094-2111.
    View in: PubMed
    Score: 0.086
  2. Men1 maintains exocrine pancreas homeostasis in response to inflammation and oncogenic stress. Proc Natl Acad Sci U S A. 2020 03 24; 117(12):6622-6629.
    View in: PubMed
    Score: 0.079
  3. Dicer1 Phosphomimetic Promotes Tumor Progression and Dissemination. Cancer Res. 2019 05 15; 79(10):2662-2668.
    View in: PubMed
    Score: 0.074
  4. Somatic Trp53 mutations differentially drive breast cancer and evolution of metastases. Nat Commun. 2018 09 27; 9(1):3953.
    View in: PubMed
    Score: 0.072
  5. Contrasting effects of an Mdm2 functional polymorphism on tumor phenotypes. Oncogene. 2018 01 18; 37(3):332-340.
    View in: PubMed
    Score: 0.067
  6. Therapeutic efficacy of p53 restoration in Mdm2-overexpressing tumors. Mol Cancer Res. 2014 Jun; 12(6):901-11.
    View in: PubMed
    Score: 0.052
  7. Multiple stress signals activate mutant p53 in vivo. Cancer Res. 2011 Dec 01; 71(23):7168-75.
    View in: PubMed
    Score: 0.044
  8. Spontaneous tumorigenesis in mice overexpressing the p53-negative regulator Mdm4. Cancer Res. 2010 Sep 15; 70(18):7148-54.
    View in: PubMed
    Score: 0.041
  9. Mdm4 loss in the intestinal epithelium leads to compartmentalized cell death but no tissue abnormalities. Differentiation. 2009 Jun; 77(5):442-9.
    View in: PubMed
    Score: 0.037
  10. The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev. 2008 May 15; 22(10):1337-44.
    View in: PubMed
    Score: 0.035
  11. Mtbp haploinsufficiency in mice increases tumor metastasis. Oncogene. 2008 Mar 20; 27(13):1813-20.
    View in: PubMed
    Score: 0.033
  12. Mammary tumor modifiers in BALB/cJ mice heterozygous for p53. Mamm Genome. 2007 May; 18(5):300-9.
    View in: PubMed
    Score: 0.033
  13. Pancreatic Epithelial IL17/IL17RA Signaling Drives B7-H4 Expression to Promote Tumorigenesis. Cancer Immunol Res. 2024 Sep 03; 12(9):1170-1183.
    View in: PubMed
    Score: 0.027
  14. Organization, expression, and localization of the murine mdmx gene and pseudogene. Gene. 2001 May 30; 270(1-2):277-83.
    View in: PubMed
    Score: 0.022
  15. Wnt/?-catenin-mediated p53 suppression is indispensable for osteogenesis of mesenchymal progenitor cells. Cell Death Dis. 2021 05 21; 12(6):521.
    View in: PubMed
    Score: 0.022
  16. The Common Germline TP53-R337H Mutation Is Hypomorphic and Confers Incomplete Penetrance and Late Tumor Onset in a Mouse Model. Cancer Res. 2021 05 01; 81(9):2442-2456.
    View in: PubMed
    Score: 0.021
  17. High metastatic potential in mice inheriting a targeted p53 missense mutation. Proc Natl Acad Sci U S A. 2000 Apr 11; 97(8):4174-9.
    View in: PubMed
    Score: 0.020
  18. Loss of one but not two mdm2 null alleles alters the tumour spectrum in p53 null mice. J Pathol. 1999 Jul; 188(3):322-8.
    View in: PubMed
    Score: 0.019
  19. Overproduction of MDM2 in vivo disrupts S phase independent of E2F1. Cell Growth Differ. 1999 Mar; 10(3):147-54.
    View in: PubMed
    Score: 0.018
  20. Mutant p53 in concert with an interleukin-27 receptor alpha deficiency causes spontaneous liver inflammation, fibrosis, and steatosis in mice. Hepatology. 2016 Mar; 63(3):1000-12.
    View in: PubMed
    Score: 0.015
  21. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature. 1995 Nov 09; 378(6553):203-6.
    View in: PubMed
    Score: 0.015
  22. Mutant p53 accumulates in cycling and proliferating cells in the normal tissues of p53 R172H mutant mice. Oncotarget. 2015 Jul 20; 6(20):17968-80.
    View in: PubMed
    Score: 0.014
  23. Loss of the novel tumour suppressor and polarity gene Trim62 (Dear1) synergizes with oncogenic Ras in invasive lung cancer. J Pathol. 2014 Sep; 234(1):108-19.
    View in: PubMed
    Score: 0.013
  24. Inhibition of endothelial p53 improves metabolic abnormalities related to dietary obesity. Cell Rep. 2014 Jun 12; 7(5):1691-1703.
    View in: PubMed
    Score: 0.013
  25. USP15 stabilizes MDM2 to mediate cancer-cell survival and inhibit antitumor T cell responses. Nat Immunol. 2014 Jun; 15(6):562-70.
    View in: PubMed
    Score: 0.013
  26. The p53-Mdm2 feedback loop protects against DNA damage by inhibiting p53 activity but is dispensable for p53 stability, development, and longevity. Genes Dev. 2013 Sep 01; 27(17):1857-67.
    View in: PubMed
    Score: 0.013
  27. Mutant p53 prolongs NF-?B activation and promotes chronic inflammation and inflammation-associated colorectal cancer. Cancer Cell. 2013 May 13; 23(5):634-46.
    View in: PubMed
    Score: 0.012
  28. Loss of PML cooperates with mutant p53 to drive more aggressive cancers in a gender-dependent manner. Cell Cycle. 2013 Jun 01; 12(11):1722-31.
    View in: PubMed
    Score: 0.012
  29. p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer. Cancer Cell. 2012 Jun 12; 21(6):793-806.
    View in: PubMed
    Score: 0.012
  30. Mutant p53 disrupts role of ShcA protein in balancing Smad protein-dependent and -independent signaling activity of transforming growth factor-? (TGF-?). J Biol Chem. 2011 Dec 23; 286(51):44023-44034.
    View in: PubMed
    Score: 0.011
  31. Rpl27a mutation in the sooty foot ataxia mouse phenocopies high p53 mouse models. J Pathol. 2011 Aug; 224(4):540-52.
    View in: PubMed
    Score: 0.011
  32. Restoring expression of wild-type p53 suppresses tumor growth but does not cause tumor regression in mice with a p53 missense mutation. J Clin Invest. 2011 Mar; 121(3):893-904.
    View in: PubMed
    Score: 0.011
  33. p53 prevents progression of nevi to melanoma predominantly through cell cycle regulation. Pigment Cell Melanoma Res. 2010 Dec; 23(6):781-94.
    View in: PubMed
    Score: 0.010
  34. p53 status in stromal fibroblasts modulates tumor growth in an SDF1-dependent manner. Cancer Res. 2010 Dec 01; 70(23):9650-8.
    View in: PubMed
    Score: 0.010
  35. A deficiency in Mdm2 binding protein inhibits Myc-induced B-cell proliferation and lymphomagenesis. Oncogene. 2010 Jun 03; 29(22):3287-96.
    View in: PubMed
    Score: 0.010
  36. An inducible mouse model for skin cancer reveals distinct roles for gain- and loss-of-function p53 mutations. J Clin Invest. 2007 Jul; 117(7):1893-901.
    View in: PubMed
    Score: 0.008
  37. Loss of Gcn5 acetyltransferase activity leads to neural tube closure defects and exencephaly in mouse embryos. Mol Cell Biol. 2007 May; 27(9):3405-16.
    View in: PubMed
    Score: 0.008
  38. p53-independent functions of the p19(ARF) tumor suppressor. Genes Dev. 2000 Sep 15; 14(18):2358-65.
    View in: PubMed
    Score: 0.005
  39. Effective treatment of early endobronchial cancer with regional administration of liposome-p53 complexes. J Natl Cancer Inst. 1998 Aug 05; 90(15):1130-7.
    View in: PubMed
    Score: 0.004
  40. mdm2 deletion does not alter growth characteristics of p53-deficient embryo fibroblasts. Oncogene. 1996 Oct 17; 13(8):1731-6.
    View in: PubMed
    Score: 0.004
  41. Developmental control of transcription of the CAT reporter gene by a truncated mouse alphafetoprotein gene regulatory region in transgenic mice. Mol Reprod Dev. 1995 Sep; 42(1):1-6.
    View in: PubMed
    Score: 0.004
  42. The expression of viral and cellular genes in papillomas of the choroid plexus induced in transgenic mice. Prog Clin Biol Res. 1988; 284:163-86.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.